Horizon Discovery Group Plc (HZD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Horizon Discovery Group Plc (HZD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH132463D
  • |
  • Pages: 94
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Horizon Discovery Group plc (Horizon Discovery) is a life science company that discovers and develops genetically-modified cell lines using a proprietary translational genomics platform, consisting of an array of gene editing tools that help change almost any endogenous gene sequence of human or mammalian cell-lines. The company's products include cell lines, reference standards and in vivo models. It also offers services such as CRISPR screening, combination screening, in vivo assay services and cell-based assays. Horizon Discovery provides its products and services to genomic research organizations, pharmaceutical, biotechnology and diagnostic companies, and academic research centers for the formulation of customized medicines. The company operates in Austria, the UK and the US. Horizon Discovery is headquartered in Cambridge, the UK.

Horizon Discovery Group Plc (HZD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Horizon Discovery Group Plc, Medical Devices Deals, 2012 to YTD 2018

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deal Details

Asset Purchase

Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus

Venture Financing

Horizon Discovery Raises USD10.5 Million In Final Closing Of Series C Financing

Partnerships

Horizon Discovery Enters into Licensing Agreement for Transposon Based Technology Platform

Horizon Discovery Enters Into Licensing Agreement With ATCC

Horizon Discovery Enters into Co-Development Agreement with Roche Diagnostics

Horizon Discovery Enters into Research Agreement with Solentim

Horizon Discovery Enters into Agreement with Fulcrum Therapeutics

Horizon Discovery Enters into Agreement with Ubiquigent

Horizon Discovery Forms Joint Venture with Centauri Therapeutics

Horizon Discovery Partners with Axol Bioscience

Horizon Discovery Enters into Agreement with Swift Biosciences

Horizon Discovery Enters into Research Agreement with Redx Pharma

Horizon Discovery Enters into Co-Development Agreement with DefiniGEN

CareDx Enters into Co-Development Agreement with Horizon Discovery

Horizon Discovery Enters into Agreement with Thermo Fisher Scientific

Horizon Discovery Enters Into Marketing Agreement With Thermo Fisher

Horizon Discovery Enters into Distribution Agreement with Haplogen Genomics

Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma

Horizon Discovery Enters Into Co-Development Agreement With Desktop Genetics

Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery

Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing

Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery

Horizon Discovery Enters Into Agreement With Domainex To Support Oncology Program

Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines

Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine

Licensing Agreements

Horizon Discovery Enters into Licensing Agreement with US Immuno-Oncology Company

ATUM Enters into Licensing Agreement with Horizon Discovery

Horizon Discovery Enters into Licensing Agreement with ATUM

Horizon Discovery Group Enters into Licensing Agreement with AmplyCell

Horizon Discovery Enters into Licensing Agreement with Servier Lab

Abcam Enters into Licensing Agreement with Horizon Discovery

Horizon Discovery Extends Licensing Agreement with ERS Genomics

Horizon Discovery And AstraZeneca Enter Into Licensing Agreement To Develop Cancer Therapies

Horizon Discovery Group Enters into Licensing Agreement

Horizon Discovery Enters into Licensing Agreement with Wistar Institute

Horizon Discovery Enters into Licensing Agreement with ProteoNic

LakePharma Enters into Licensing Agreement with Horizon Discovery

Horizon Discovery Enters into Licensing Agreement with Stanford University

Horizon Discovery Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System

Horizon Discovery Enters Into Licensing Agreement With AstraZeneca

Horizon Discovery Enters Into Licensing Agreement With Harvard University For Crispr Gene Editing Technology

Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology

NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology

Horizon Discovery Enters Into Licensing Agreement With Rosalind Franklin University of Medicine and Science

Equity Offering

Horizon Discovery Raises USD104.6 million in Private Placement of Shares

Horizon Discovery Raises USD38.5 Million in Private Placement of Shares

Horizon Discovery Completes IPO For USD66.7 Million

Acquisition

Horizon Discovery Acquires GE Healthcare Dharmacon from General Electric for USD85 Million

Horizon Discovery Acquires Haplogen Genomics for USD15 Million

Horizon Discovery to Acquire Sage Labs for USD48 Million

Horizon Discovery Group Plc-Key Competitors

Horizon Discovery Group Plc-Key Employees

Horizon Discovery Group Plc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Recent Developments

Financial Announcements

Sep 26, 2017: Horizon Discovery Group: Interim Results For The Six Months Ended 30 June 2017

May 30, 2017: Horizon Discovery Group: Preliminary Results for the Year Ended 31 December 2016

Corporate Communications

Mar 02, 2018: Horizon Discovery Group: Board Change

Feb 20, 2018: Horizon Discovery Announces Leadership Changes

Legal and Regulatory

Jul 03, 2017: Horizon Discovery announces inclusion of its Reference Standards in successful FDA approval of an oncology companion diagnostic test with leading next generation sequencing company

Government and Public Interest

Jul 17, 2017: Sphere Fluidics and Partners Win Major InnovateUK Grant to Develop the World's First Desktop Genome Editing System

May 22, 2017: Horizon Discovery Announces New Gene Editing Technology Platform for Research and Therapeutic Applications

Product News

Nov 14, 2017: Horizon Discovery's Dharmacon introduces Edit-R CRISPRa reagent platform for genome-wide CRISPR activation

Aug 01, 2017: Horizon Discovery announces release of high quality, well annotated CHO genome sequence to drive innovation in bioproduction

May 26, 2017: Horizon Discovery introduces four BRAF resistant melanoma PDX models

Other Significant Developments 9

Sep 18, 2017: Horizon Discovery announces launch of Genome-Wide CRISPRi and CRISPRa Screening Services 9

May 09, 2017: Horizon Discovery Announces Update on its Immuno-Oncology Platform including Strong Uptake of Product and Service Offerings

Jan 24, 2017: Horizon Discovery Group: Trading Update

Jan 13, 2017: International Trade Minister Greg Hands visits fast-growing Cambridge life sciences company

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer

List of Figures

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Horizon Discovery Group Plc, Medical Devices Deals, 2012 to YTD 2018

List of Tables

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2016

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Horizon Discovery Group Plc, Deals By Therapy Area, 2012 to YTD 2018

Horizon Discovery Group Plc, Medical Devices Deals, 2012 to YTD 2018

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus

Horizon Discovery Raises USD10.5 Million In Final Closing Of Series C Financing

Horizon Discovery Enters into Licensing Agreement for Transposon Based Technology Platform

Horizon Discovery Enters Into Licensing Agreement With ATCC

Horizon Discovery Enters into Co-Development Agreement with Roche Diagnostics

Horizon Discovery Enters into Research Agreement with Solentim

Horizon Discovery Enters into Agreement with Fulcrum Therapeutics

Horizon Discovery Enters into Agreement with Ubiquigent

Horizon Discovery Forms Joint Venture with Centauri Therapeutics

Horizon Discovery Partners with Axol Bioscience

Horizon Discovery Enters into Agreement with Swift Biosciences

Horizon Discovery Enters into Research Agreement with Redx Pharma

Horizon Discovery Enters into Co-Development Agreement with DefiniGEN

CareDx Enters into Co-Development Agreement with Horizon Discovery

Horizon Discovery Enters into Agreement with Thermo Fisher Scientific

Horizon Discovery Enters Into Marketing Agreement With Thermo Fisher

Horizon Discovery Enters into Distribution Agreement with Haplogen Genomics

Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma

Horizon Discovery Enters Into Co-Development Agreement With Desktop Genetics

Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery

Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing

Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery

Horizon Discovery Enters Into Agreement With Domainex To Support Oncology Program

Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines

Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine

Horizon Discovery Enters into Licensing Agreement with US Immuno-Oncology Company

ATUM Enters into Licensing Agreement with Horizon Discovery

Horizon Discovery Enters into Licensing Agreement with ATUM

Horizon Discovery Group Enters into Licensing Agreement with AmplyCell

Horizon Discovery Enters into Licensing Agreement with Servier Lab

Abcam Enters into Licensing Agreement with Horizon Discovery

Horizon Discovery Extends Licensing Agreement with ERS Genomics

Horizon Discovery And AstraZeneca Enter Into Licensing Agreement To Develop Cancer Therapies

Horizon Discovery Group Enters into Licensing Agreement

Horizon Discovery Enters into Licensing Agreement with Wistar Institute

Horizon Discovery Enters into Licensing Agreement with ProteoNic

LakePharma Enters into Licensing Agreement with Horizon Discovery

Horizon Discovery Enters into Licensing Agreement with Stanford University

Horizon Discovery Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System

Horizon Discovery Enters Into Licensing Agreement With AstraZeneca

Horizon Discovery Enters Into Licensing Agreement With Harvard University For Crispr Gene Editing Technology

Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology

NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology

Horizon Discovery Enters Into Licensing Agreement With Rosalind Franklin University of Medicine and Science

Horizon Discovery Raises USD104.6 million in Private Placement of Shares

Horizon Discovery Raises USD38.5 Million in Private Placement of Shares

Horizon Discovery Completes IPO For USD66.7 Million

Horizon Discovery Acquires GE Healthcare Dharmacon from General Electric for USD85 Million

Horizon Discovery Acquires Haplogen Genomics for USD15 Million

Horizon Discovery to Acquire Sage Labs for USD48 Million

Horizon Discovery Group Plc, Key Competitors

Horizon Discovery Group Plc, Key Employees

Horizon Discovery Group Plc, Other Locations

Horizon Discovery Group Plc, Subsidiaries

Horizon Discovery Group Plc, Joint Venture

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license

Single User License
USD 250 INR 16863
Site License
USD 500 INR 33725
Corporate User License
USD 750 INR 50588

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com